[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1994


Author Affiliations

Trento, Italy

Feltre, Italy

Department of Pathology S Chiara Hospital 38100 Trento, Italy

Arch Dermatol. 1994;130(4):518-519. doi:10.1001/archderm.1994.01690040126023

We appreciated very much the comments by McGregor et al concerning our article dealing with p53 expression in human nevi and melanomas.1 We completely agree with McGregor et al concerning the prognostic significance of p53 immunoreactivity. We, too, are interested in evaluating p53 immunoreactivity in human neoplasms in relation to its possible value as a predictor of more aggressive disease.2,3 However, our comments1 were not aimed at denying the possible prognostic value of p53 immunoreactivity in skin melanomas. Indeed, we found a higher percentage of p53-positive cases among melanoma metastases than in primary lesions, a fact that may be supportive of the hypothesis that p53 accumulation in melanomas might be correlated with tumor progression. Moreover, as shown in the table on page 740 of our article,1 the prevalence of thin melanomas in the group with more than 1% of positive cells is low (one of seven

First Page Preview View Large
First page PDF preview
First page PDF preview